Health and Fitness Health and Fitness
Wed, December 22, 2010
[ Wed, Dec 22nd 2010 ] - Market Wire
BioCryst Initiates a Phase 2b Study of BCX4208 as .. Gout Patients Not Responding to Allopurinol Alone
[ Wed, Dec 22nd 2010 ] - Market Wire
Aanvraag Biogen Idec en Elan voor aanpassing bijs .. et PML-risico met antilichamen voor anti-JC virus
[ Wed, Dec 22nd 2010 ] - Market Wire
Biogen Idec e Elan chiedono l'aggiornamento dell' .. ludendo lo status dell'anticorpo anti virus JC, c
[ Wed, Dec 22nd 2010 ] - Market Wire
Biogen Idec et Elan d©posent des demandes de mis .. TYSABRI dans le but da?aider stratifier le risque
[ Wed, Dec 22nd 2010 ] - Market Wire
Biogen Idec und Elan stellen Antrge auf Aktualisi .. n fr TYSABRI, die mittels des JC-Virus-Antikrpers
Tue, December 21, 2010
[ Tue, Dec 21st 2010 ] - Market Wire
Biogen Idec and Elan Submit Applications to Updat .. elp Stratify Risk of PML with Anti-JC Virus Antib
[ Tue, Dec 21st 2010 ] - Market Wire
CardioNet, Inc. Completes Acquisition of Biotel Inc.
[ Tue, Dec 21st 2010 ] - Market Wire
American CareSource Holdings Names William J. Simpson, Jr. Chief Operating Officer
[ Tue, Dec 21st 2010 ] - Market Wire
Vertex Provides Update to Ongoing Phase 2 Study E .. aprevir and VX-222 for the Treatment of Hepatitis
[ Tue, Dec 21st 2010 ] - Market Wire
Teva and Takeda Settle Generic ACTOS® and ACTOplus met® Litigation
[ Tue, Dec 21st 2010 ] - Market Wire
Humana Inc. Completes Acquisition of Concentra Inc.
[ Tue, Dec 21st 2010 ] - Market Wire
Enzon Board Authorizes Share Repurchase Program
[ Tue, Dec 21st 2010 ] - Market Wire
Landmark Medtronic CoreValve® U.S. Clinical Trial Begins
[ Tue, Dec 21st 2010 ] - Market Wire
Law Office of Jonathan M. Stein, P.L. Investigate .. y Duty by the Board of Martek Biosciences Corpora
[ Tue, Dec 21st 2010 ] - Market Wire
Kendall Law Group Investigates Martek Biosciences Corporation for Shareholders
[ Tue, Dec 21st 2010 ] - Market Wire
Bernstein Liebhard LLP Announces Investigation of .. uisition of Martek Biosciences Corporation by DSM
[ Tue, Dec 21st 2010 ] - Market Wire
Four Rivers (trading as 'Verta Energy') Receives .. roposed UK Waste-to-Energy Plant to Generate Elec
[ Tue, Dec 21st 2010 ] - Market Wire
Rigrodsky & Long, P.A. Investigates Martek Biosciences Corporation Buyout
[ Tue, Dec 21st 2010 ] - Market Wire
A Letter From the President of Biomagnetics Diagnostics Corp.
[ Tue, Dec 21st 2010 ] - Market Wire
Health Net Federal Services Awarded Department of .. r VA Clinics in Espanola and Las Vegas, New Mexic
[ Tue, Dec 21st 2010 ] - Market Wire
Emeritus Senior Living Receives Best of the Web Award 2011
[ Tue, Dec 21st 2010 ] - Market Wire
Allos Therapeuticsa? Marketing Authorisation Appl .. cepted for Review by European Medicines Agency (E
[ Tue, Dec 21st 2010 ] - Market Wire
IntegraMed® CFO John Hlywak to Retire at Year-End; Appoints Tim Sheehan as Interim-CFO
[ Tue, Dec 21st 2010 ] - Market Wire
Pro-Pharmaceuticals & Mount Sinai School of Medic .. nnounce New Liver Fibrosis Research Collaboration
[ Tue, Dec 21st 2010 ] - Market Wire
Amedisys to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Tue, Dec 21st 2010 ] - Market Wire
Biogen Idec y Neurimmune suscriben acuerdo para tres programas de enfermedades neurodegenerativas
[ Tue, Dec 21st 2010 ] - Market Wire
Biogen Idec en Neurimmune maken overeenkomst beke .. drie programmaa?s voor neurodegeneratieve ziekten
[ Tue, Dec 21st 2010 ] - Market Wire
Biogen Idec et Neurimmune s'accordent sur trois p .. rammes ciblant les maladies neurod©g©n©ratives
[ Tue, Dec 21st 2010 ] - Market Wire
Biogen Idec und Neurimmune melden Vereinbarung be .. drei Programme fr neurodegenerative Erkrankungen
Mon, December 20, 2010
[ Mon, Dec 20th 2010 ] - Market Wire
Biogen Idec e Neurimmune annunciano l'accordo su .. rogrammi relativi alle malattie neurodegenerative

Biogen Idec e Neurimmune annunciano l'accordo su tre programmi relativi alle malattie neurodegenerative


Published on 2010-12-20 16:25:58 - Market Wire
  Print publication without navigation


WESTON (Mass., USA) e ZURIGO--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) e [ Neurimmune Holding AG ] hanno oggi annunciato che Biogen Idec ha acquisito una sussidiaria di Neurimmune, oltre ai diritti mondiali su tre programmi immunoterapici pre-clinici. I tre programmi sono incentrati sulla scoperta e lo sviluppo di nuovi anticorpi umani specifici per tre target del sistema nervoso centrale: alfa-sinucleina, tau e TDP-43. Questi obiettivi sono considerati importanti per il trattamento e la prevenzione di una vasta gamma di malattie neurodegenerative, come il morbo di Parkinson e di Alzheimer e la sclerosi laterale amiotrofica (SLA). Biogen Idec effettuer un pagamento iniziale di $ 32,5 milioni e fino a $ 395 milioni in pagamenti contingenti.

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.

Contributing Sources